Abarceo is a preclinical stage company, a spinout of Lund University Diabetes Center. The company has expertise in the molecular and genetic causes of beta cell dysfunction in type 2 diabetes and has identified a novel diabetes target responsible for the dysfunction, VDAC-1. By blocking VDAC-1 with a small molecule blocker beta cells are returned to a functional state in a durable and disease modifying manner allowing patients to produce sufficient insulin, naturally. The company is fundraising to support preclinical development.
Employees: 11-50
Founded date: 2017
Investors 1
| Date | Name | Website |
| 02.03.2021 | Almi Inves... | almi.se |
Mentions in press and media 1
| Date | Title | Description |
| 13.06.2020 | 42 start-ups reach EIT Health Catapult Semi-finals | The EIT Health Catapult, currently in its fifth year of operation, is a training and competition programme that boosts the development of European health start-ups by exposing them to top quality experts and international investors. The 42... |